IRWD at a glance
IRONWOOD PHARMACEUTICALS INC (IRWD, SEC CIK 1446847) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding IRONWOOD PHARMACEUTICALS INC (IRWD) shares worth $296.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Gaskins Tammi L on November 16, 2026 of 5,919 shares at $4.81 per share.
- In the last 90 days, IRWD insiders reported 0 open-market purchases ($0) and 1 open-market sale ($28K) on Form 4, a net sale of $28K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $296.2M
- −15.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$28K
- 13F holders
- 28 funds
- $296.9M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $133.0M, up $11.0M YoY, driven by LINZESS U.S. net-profit share
- Operating margin 70.0% vs 61.8% YoY, with operating income $93.1M vs $75.5M
- Apraglutide R&D $25.2M, up from $17.8M, the largest pipeline expense
- Cash $86.4M; operating cash flow $130.8M, financing outflow $259.7M
- STARS-2 recruiting; regulatory filing for apraglutide planned in 2029, subject to results
Risk Factors
- No material risk-factor changes disclosed; Item 1A contains no substantive risk discussion
- Partner concentration: AbbVie accounted for $132.1 million of $132.7 million accounts receivable
- Regulatory and legal exposure: Ferring settlement requires remaining $5.0 million payment by December 31, 2026
- Liquidity risk: cash declined to $86.4 million while revolving debt remained $325.0 million
- Commercial concentration: LINZESS U.S. collaboration generated $344.2 million of nine-month revenue through AbbVie
AI summary of the IRWD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s operating update and financial results details
Item EX-99.1: Item EX-99.1
- Raised 2026 LINZESS U.S. sales guidance to $1.20-$1.25B, signaling sustained demand and improved net pricing
- Raised 2026 revenue guidance to $485-$510M and adjusted EBITDA above $350M, strengthening earnings expectations
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO succession effective January 1, 2027: Tammi Gaskins replaces Thomas McCourt after his 17 years with Ironwood
- Gaskins joins the Board, expanding director count from eight to nine; McCourt remains a director
Item EX-99.1: Item EX-99.1
- Tammi Gaskins becomes CEO and joins the board effective January 1, 2027
- Tom McCourt retires as CEO after 17 years, remaining on Ironwood’s board
Item EX-99.1: Item EX-99.1
- Raised 2026 guidance: LINZESS U.S. sales $1.15–$1.20B, revenue $460–$485M, adjusted EBITDA above $310M
- Q2 LINZESS sales $282.3M, up 14%, supported by 4% demand growth and improved net pricing
Item 2.02: Results of Operations and Financial Condition
- Press release covers Ironwood’s recent business activities and quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed financial results and business update
AI summaries of IRWD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IRWD
Don't miss the next IRWD filing
- Alerts as it files. A push when IRWD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IRWD, by share count.
- Ask anything. An AI agent that reads every IRWD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gaskins Tammi L | Sell | Nov 16, 2026 | 5,919 | $4.81 |
| DENNER ALEXANDER J | A | Sep 15, 2026 | 3,694 | - |
| Silber Jeffrey | A | Jul 20, 2026 | 137,036 | - |
| Silver Ronald | Sell | Jul 7, 2026 | 127,890 | $4.52 |
| McHugh Julie | A | Jun 16, 2026 | 63,481 | - |
| McHugh Julie | Sell | Jun 16, 2026 | 21,571 | $3.73 |
| Moukheibir Catherine | A | Jun 16, 2026 | 63,481 | - |
| Kessler Marla L | A | Jun 16, 2026 | 63,481 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $351.4M | $296.2M |
| Operating Income | - | $93.1M | $98.5M |
| Net Income | -$1.0B | $880K | $24.0M |
| Op. Margin | - | 26.5% | 33.3% |
| Net Margin | - | 0.3% | 8.1% |
| Balance Sheet | |||
| Total Assets | $471.1M | $350.9M | $396.9M |
| Equity | - | -$301.3M | -$261.8M |
| ROE | - | -0.3% | -9.2% |
| Per Share | |||
| EPS | $-6.45 | $0.01 | $0.15 |
| Cash Flow | |||
| Operating CF | - | $103.5M | $127.0M |
| CapEx | $273K | $142K | $34K |
Source: XBRL data in IRONWOOD PHARMACEUTICALS INC (IRWD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IRWD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $296.9M |
| Q2 2026 | 28 | $346.3M |
| Q1 2026 | 28 | $265.4M |
| Q4 2025 | 24 | $230.4M |
| Q3 2025 | 26 | $86.0M |
| Q2 2025 | 27 | $42.7M |
| Q1 2025 | 26 | $73.9M |
| Q4 2024 | 23 | $207.0M |
- BlackRock+686.9K (+4%)
- Principal Financial Group+306.9K (+2552%)
- Franklin Resources+261.6K (+26%)
- Prudential Financial+188.3K (+35%)
- Dimensional Fund Advisors+131.7K (+5%)
- Bank of America Corp−3.46M (-40%)
- State Street Corp−2.09M (-24%)
- Two Sigma Investments−701.2K (-15%)
- AQR Capital Management−641.6K (-10%)
- Goldman Sachs Group−570.5K (-17%)
- FMR LLC (Fidelity)−909.5K
- Truist Financial−35.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IRWD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
IRWD SEC filings: frequently asked questions
Are IRWD insiders buying or selling?
In the last 90 days, IRONWOOD PHARMACEUTICALS INC (IRWD) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $28,470 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IRWD stock?
As of September 30, 2026, the largest IRONWOOD PHARMACEUTICALS INC (IRWD) holders among the 13F filers tracked by SignalX were BlackRock ($73.3 million), Renaissance Technologies LLC ($31.9 million), State Street Corp ($26.7 million), Vanguard Capital Management LLC ($26.3 million), AQR Capital Management ($23.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IRWD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.
What did IRWD report in its latest 8-K?
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026.
What are the latest IRWD SEC filings?
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 18, 2026.
What is IRWD's SEC CIK number?
IRONWOOD PHARMACEUTICALS INC (IRWD)'s SEC Central Index Key (CIK) is 1446847. EDGAR lists every IRWD filing under that number.
Ask anything about IRWD
The research agent reads IRWD's filings, financials, insider trades and 13F holders, then answers with sources.